D
Summit Therapeutics Inc. SMMT
$17.37 $0.523.09% NASDAQ
Recommendation
Prev Close
$16.85
Volume
3,545,980
Avg Vol (90D)
3,178,866
Market Cap
$12.99B
Dividend & Yield
--
52-Week Range
$15.55 - $36.91
P/E (TTM)
--
EPS (TTM)
-$1.25
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Why Wall Street Is Backing These 3 Comeback Stocks
10/28/2025 - MarketBeat
ABBV vs. MRK: An Oncology-Immunology Showdown for Investors
1/22/2026 - Zacks Investment Research
A Look At Summit Therapeutics (SMMT) Valuation After Ivonescimab FDA Filing And New GSK Collaboration
1/22/2026 - Simply Wall St
TOTH FINANCIAL ADVISORY CORP Buys 90 Shares of Summit Therapeutics Inc (SMMT)
1/20/2026 - GuruFocus
Marquette Asset Management, LLC Buys 28 Shares of Summit Therapeutics Inc (SMMT)
1/20/2026 - GuruFocus
Summit Therapeutics (SMMT, $17.27) entered Downtrend as Momentum indicator drops below 0 level on Jan 15, 2026
1/16/2026 - Tickeron - Technical Analysis
Is Summit Therapeutics (SMMT) Building a Durable Oncology Combination Platform With Ivonescimab's Expanding Reach?
1/15/2026 - Simply Wall St
Why Merck's 32% Rally Isn't Enough to Change the Bearish View
1/15/2026 - Zacks Investment Research
Summit Therapeutics PLC (NASDAQ:SMMT) Receives Consensus Rating of "Hold" from Brokerages
1/15/2026 - MarketBeat
Summit Therapeutics PLC $SMMT Shares Purchased by APEIRON CAPITAL Ltd
1/15/2026 - MarketBeat
Summit Therapeutics (SMMT, $16.81) Moving Average Convergence Divergence (MACD) Histogram turned negative on January 13, 2026
1/14/2026 - Tickeron - Stocks
Analysts Offer Insights on Healthcare Companies: Treace Medical Concepts (TMCI), Corcept Therapeutics (CORT) and Summit Therapeutics (SMMT)
1/14/2026 - TipRanks Financial Blog
Assessing Summit Therapeutics (SMMT) Valuation After Ivonescimab FDA Filing And New GSK Trial Collaboration
1/14/2026 - Simply Wall St
ABBV Inks Drug Pricing Deal With Trump, Joins PD-1xVEGF Bandwagon
1/13/2026 - Zacks Investment Research
Summit Therapeutics (SMMT, $17.04) RSI Indicator left the overbought zone on January 12, 2026
1/13/2026 - Tickeron - Technical Analysis
Summit Therapeutics (SMMT, $17.04) price exceeded its 50-day Moving Average on January 12, 2026
1/13/2026 - Tickeron - Technical Analysis
Summit Therapeutics (SMMT, $17.04) entered Downtrend as Momentum indicator drops below 0 level on Jan 12, 2026
1/13/2026 - Tickeron - Technical Analysis
Summit Therapeutics (SMMT, $17.04) Stochastic Oscillator left the overbought zone on January 12, 2026
1/13/2026 - Tickeron - Technical Analysis
Is It Too Late To Consider Summit Therapeutics (SMMT) After A 3x Three-Year Surge?
1/13/2026 - Simply Wall St
Summit Therapeutics Inc at JPMorgan Healthcare Conference Transcript
1/13/2026 - GuruFocus
Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 13.4% - What's Next?
1/12/2026 - MarketBeat
Summit Therapeutics Inc. (SMMT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
1/12/2026 - SeekingAlpha
Summit Therapeutics Inc. (SMMT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
1/12/2026 - Seeking Alpha: Transcripts
2 Biotech Stocks That Could Soar This Year
1/12/2026 - Fool.com Headlines
Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in ...
1/12/2026 - GuruFocus
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$934.99M
EBIT (TTM)
-$935.11M
Net Income (TTM)
-$921.62M
Balance Sheet
Total Assets (Q)
$261.73M
Total Debt (Q)
$5.43M
Total Liabilities (Q)
$69.47M
Book Value Per Share (Q)
$0.2583
Cash Flow
Cash from Operations (TTM)
-$269.67M
Cash from Investing (TTM)
$394.33M
Cash from Financing (TTM)
$20.10M
Net Change in Cash (TTM)
$144.78M
Filings
Filing Date
Monday, October 20, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Feb 23 and 27 (est)
Price History
Loading...
Beta
1.74
7-Day Total Return
1.94%
30-Day Total Return
-6.74%
60-Day Total Return
-9.91%
90-Day Total Return
-8.29%
Year to Date Total Return
-0.86%
1-Year Total Return
-26.15%
2-Year Total Return
360.74%
3-Year Total Return
289.46%
5-Year Total Return
210.73%
52-week Low
Apr 07, 2025 - $15.55
52-week High
Apr 24, 2025 - $36.91
Valuation
Market Cap
$12.99B - Large Cap
Enterprise Value
$12.76B
Price/Sales (TTM)
--
Price/Book (Q)
65.23
Dividends and Shares
Shares Outstanding
743.42M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.smmttx.com
Phone Number
305 203 2034
Address
601 Brickell Key Drive
Miami, FL 33131
Country
United States
Year Founded
2003
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its... more
NASDAQ 01/22/2026 4:00PM Eastern Quotes delayed